1. Gladman D, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14–ii17.
2. Liu JT, Yeh HM, Liu SY, et al. Psoriatic arthritis: Epidemiology, diagnosis, and treatment. World J Orthop 2014;5(4):537–543.
3. Slobodin G, Rosner I, Rozenbaum M, et al. Psoriatic arthropathy: where now? Isr Med Assoc J 2009;11:430–434.
4. de Vlam K, Gottlieb AB, Mease PJ. Current concepts in psoriatic arthritis: pathogenesis and management. Acta Derm Venereol 2014;94(6):627–34.
5. Kavanaugh A, Philip Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP). Survey Rheumatol Ther 2016;3(1):91–102.
6. Ritchlin C, Colbert RA, Gladman D. Psoriatic arthritis. New Engl J Med 2017;376(10):957–970.
7. Tillett W, Jadon D, Shaddick G, et al. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis 2013;72(8): 1358–1.
8. Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994;33:834–839.
9. Rajendran CP, Ledge SG, Rani KP, et al. Psoriatic arthritis. J Assoc Physicians India 2003;51:1065–1068.
10. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991;30:245–250.
11. Madland TM, Apalset EM, Johannessen AE, et al. Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway. J Rheumatol 2005;32: 1918–1922.
12. Ash ZR, Tinazzi I, Gallego CC, et al. Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Ann Rheum Dis 2012;71(4):553–6.
13. Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 2012;71(8):1267–72.
14. Chandran V, Schentag CT, Brockbank JE, et al. Familial aggregation of psoriatic arthritis. Ann Rheum Dis 2009;68(5):664–7.
15. Acosta Felquer ML, FitzGerald O. Peripheral joint involvement in psoriatic arthritis patients. Clin Exp Rheumatol 2015;33(5 Suppl 93):S26–30.
16. Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994;33:133–138.
17. Charlton R, Amelia Green A, Shaddick G, et al. Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study. Ann Rheum Dis 2018;77(2):277–280.
18. Caso F, Del Puente A, Oliviero F, et al. Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross- -sectional study. Clin Rheumatol 2018;37(3):579–586.
19. Liew JW, Ramiro S, Gensler LS. Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriaticarthritis. Best Pract Res Clin Rheumatol 2018;32(3):369–389.
20. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–2673.
21. Ibrahim GH, Buch MH, Lawson C, et al. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol 2009;27:469–74.
22. Coates LC T Aslam T, Al Balushi F, et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol 2013;168(4):802–7.
23. Salaffi F, DiI Carlo M, Luchetti MM, et al. A validation study of the Simple Psoriatic Arthritis Screening (SiPAS) questionnaire to screen psoriasis patients for psoriatic arthritis. Clin Exp Rheumatol 2018;36:127–35.
24. Lai TL, Yim CW, Wong PY, et al. Hyperuricemia in Asian psoriatic arthritis patients. Int J Rheum Dis. 2018;21(4):843–9.
25. Fernandes S, Etcheto A, van der Heijde D, et al. Vitamin D status in spondyloarthritis: results of the ASAS-COMOSPA international study. Clin Exp Rheumatol 2018;36:210–4.
26. Cretu D, Gao L, Liang K, et al. Differentiating psoriatic arthritis from psoriasis without psoriatic arthritis using novel serum biomarkers. Arthritis Care Res 2018;70:454–61.
27. Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HL-A 27. Lancet 1973;1:904–7.
28. Dhir V, Aggarwal A. Psoriatic arthritis: a critical review. Clin Rev Allergy Immunol 2013;44:141–148.
29. Möller B, Bonel H, Rotzetter M, et al. Measuring finger joint cartilage by ultrasound as a promising alternative to conventional radiograph imaging. Arthritis Rheum 2009;61:435–441.
30. Porter GG. Psoriatic arthritis. Plain radiology and other imaging techniques. Baillieres Clin Rheumatol 1994;8:465–482.
31. De Simone C, Guerriero C, Giampetruzzi AR, et al. Achilles tendinitis in psoriasis: clinical and sonographic findings. J Am Acad Dermatol 2003;49:217–222.
32. Tinazzi I, McGonagle D, Zabotti A, et al. Comprehensive evaluation of finger flexor tendon entheseal soft tissue and bone changes by ultrasound can differentiate psoriatic arthritis and rheumatoid arthritis. Clin Exp Rheumatol 2018;36:785–90.
33. Moya Alvarado P, Roe Crespo E, Munozgarza FZ, et al. Subclinical enthesopathy of extensor digitorum tendon is highly prevalent and associated with clinical and ultrasound alterations of the adjacent fingernails in patients with psoriatic disease. J Eur Acad Dermatol Venereol 2018;32:1728–36.
34. Eder L, Aydin SZ, Kaeley GS, et al. Options for assessing joints and entheses in psoriatic arthritis by ultrasonography and magnetic resonance imaging: how to move forward. J Rheumatol Suppl 2018;94:44–7.
35. Runarsdottir EE, Gunnarsdottir AI, Love TJ, et al. The majority of patients with psoriatic arthritis are not eligible for randomised clinical trials. Clin Exp Rheumatol 2018;36: 1068–73.
36. Schoellnast H, Deutschmann HA, Hermann J, et al. Psoriatic arthritis and rheumatoid arthritis: findings in contrast-enhanced MRI. AJR Am J Roentgenol 2006;187:351–357.
37. Gossec L, McGonagle D, Korotaeva T, et al. Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature. J Rheumatol 2018;45(1):6–13.
38. Shoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69(8):1441–1447.
39. Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72(2):986–991.
40. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79:700–12.
41. Štofla J, Vencovský J, Pavelka K. Doporučené léčebné postupy pro psoriatickou artritidu. Čes Revmatol 2017;24(4):142–52.
42. Coates LC, Kavanaugh A, Mease PJ, et al.; Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016;68(5):1060–71.
43. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012;51:1368–77.
44. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 2015;386:2489–98.
45. Heiberg MS, Kaufmann C, Rødevand E, et al. The comparative effectiveness of anti- -TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 2007;66: 1038–42.
46. Lie E, van der Heijde D, Uhlig T, et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:671–6.
47. Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol 2019;71:1112–24.
48. Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin- 23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator- -controlled voyage 2 trial. J Am Acad Dermatol 2017;76:418–31.
49. Blauvelt A, Reich K, Tsai T-F, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol 2017;76:e69:60–9.
50. Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate- to-severe plaque psoriasis. N Engl J Med 2017;376:1551–60.
51. Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. The Lancet 2017;389:2317–27.
52. Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis 2020;79:123–31.
53. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382:780–9.
54. Behrens F, Cañete JD, Olivieri I, et al. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PSA: a systematic review of the literature. Rheumatology 2015;54:915–26.
55. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017; 377: 1537–50.
56. McInnes IB, Anderson J, Magrey M, et al. Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to non-biologic disease-modifying anti-rheumatic drugs (SELECT-PsA 1): a double-blind, randomized controlled phase 3 trial. Eular 2020 e-congress: abstract LB0001.
57. Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 2020;0:1–9.
58. Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 2016;75:1065–73.
59. Mease P. Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis? Clin Exp Rheumatol 2013;31:S59–62.